All Releases
 |
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
05.13.2013
|
11.5 KB |
|
| |
JERSEY CITY, N.J., May 13, 2013 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief Operating Officer. Mr. Sirota will be responsible for directing Optimer's corporate strategy with regard to DIFICID®.
"Eric has tremendous experience and has dem...
|
|
Optimer Reports First Quarter 2013 Financial Results
05.09.2013
|
21.8 KB |
|
| |
JERSEY CITY, N.J., May 9, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the first quarter ended March 31, 2013.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
Financial Highlights
First quarter 2013 DIFICID net product sales in the U.S. an...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
05.02.2013
|
9.3 KB |
|
| |
JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, May 9. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to ...
|
|
DIFICID® (fidaxomicin) Tablets Approved in Australia
04.26.2013
|
12.7 KB |
|
| |
JERSEY CITY, N.J., April 26, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® (fidaxomicin) tablets for the treatment of confirmed Clostridium difficile infection (CDI) in adu...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03.15.2013
|
8.9 KB |
|
| |
JERSEY CITY, N.J., March 15, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on March 14, 2013 the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 5,010 shares of common stock to 4 new employ...
|
|
Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
02.28.2013
|
24.1 KB |
|
| |
JERSEY CITY, N.J., Feb. 28, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )
Financial Highlights
2012 DIFICID net product sales in th...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02.27.2013
|
8.9 KB |
|
| |
JERSEY CITY, N.J., Feb. 27, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on February 26, 2013 the Inducement Award Sub-Committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 2,56...
|
|
Optimer Pharmaceuticals' Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
02.27.2013
|
14.0 KB |
|
| |
JERSEY CITY, N.J., Feb. 27, 2013 /PRNewswire/ -- The Board of Directors of Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of its Chairman, Dr. Henry McKinnell, as Chief Executive Officer. Dr. McKinnell was associated with Pfizer Inc., from 1971 until his retirement in 2007, including serving as P...
|
|
New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI)
02.14.2013
|
14.8 KB |
|
| |
JERSEY CITY, N.J., Feb. 14, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the February 2013 Journal of the American Geriatrics Society published results from a multivariate analysis demonstrating that advancing age is a predictor of deterioration in treatment outcomes in patients with Clostridium difficile i...
|
|
Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
02.07.2013
|
8.9 KB |
|
| |
JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Leerink Swann Global Healthcare Conference Thursday, February 14, 2013 at 2:30 p.m. Eastern Time and provide a business overview and update.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA973...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
02.07.2013
|
9.3 KB |
|
| |
JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year 2012 financial results after the NASDAQ Global Market closes on February 28. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the fin...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02.01.2013
|
8.9 KB |
|
| |
JERSEY CITY, N.J., Feb. 1, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on January 31, 2013 the Inducement Award Sub-Committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 6,240 ...
|
|
Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4 Million
01.07.2013
|
14.0 KB |
|
| |
JERSEY CITY, N.J., Jan. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on 2012 sales for DIFICID (fidaxomicin) tablets, an antibacterial drug launched in July 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older in the United States. Preliminary...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12.24.2012
|
8.9 KB |
|
| |
JERSEY CITY, N.J., Dec. 24, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 21, 2012 the Inducement Grant Sub-committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 12,0...
|
|
Optimer Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
12.20.2012
|
9.0 KB |
|
| |
JERSEY CITY, N.J., Dec. 20, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare conference on Tuesday, January 8, 2013 at 8:00 AM Pacific Time and provide a business overview and update.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97...
|
|
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
12.05.2012
|
9.1 KB |
|
| |
JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23rd Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at 2:45 PM Eastern Time in New York and provide a business overview and update.
(Logo: http://photos.prnewswire.com/p...
|
|
Optimer Pharmaceuticals and AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in Latin America
12.03.2012
|
13.8 KB |
|
| |
JERSEY CITY, N.J., Dec. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in South America, including Brazil, Central America, Mexico and the Caribbean.
(...
|
|
Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11.07.2012
|
9.4 KB |
|
| |
JERSEY CITY, N.J., Nov. 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in November. The presentations will include an overview of the company and an update on recent business activities.
(Logo: http://photos.prnewswire.com/prnh/20090...
|
|
Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
11.01.2012
|
24.2 KB |
|
| |
JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2012.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
Third Quarter 2012 Financial Highlights:
DIFICID® gross sales in the U.S. ...
|
|
Optimer Initiates Phase 3b Clinical Trial of DIFICID® for the Prevention of Clostridium difficile-Associated Diarrhea in Bone Marrow Transplant Patients
11.01.2012
|
13.6 KB |
|
| |
JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the first patient has been dosed in its DEFLECT-1, Phase 3b clinical trial of DIFICID® (fidaxomicin) tablets for the prevention of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing hematopoietic stem cell tran...
|
Delicious
Digg
Facebook
LinkedIn
Twitter